TY - JOUR
T1 - Long-term neurodevelopment of children exposed in utero to ciclosporin after maternal renal transplant
AU - Nulman, Irena
AU - Sgro, Michael
AU - Barrera, Maru
AU - Chitayat, David
AU - Cairney, John
AU - Koren, Gideon
N1 - Funding Information:
This study was financially supported by the Research Leadership for Better Pharmacotherapy During Pregnancy and Lactation, Hospital for Sick Children, Toronto, Ontario, Canada, and Novartis, Global Epidemiology, Barcelona, Spain. The authors have no conflicts of interest to declare that are directly relevant to the content of this study.
PY - 2010
Y1 - 2010
N2 - Background: Immunosuppressant therapy is essential in the prevention of organ transplant rejection. Objective: To evaluate the long-term neurodevelopmental outcomes of children following in utero ciclosporin (cyclosporine) exposure after maternal renal transplantation. Methods: A cohort study with matched controls using a prospectively collected database was conducted to assess neurocognitive and behavioral outcomes using standardized measures. Thirty-nine children exposed in utero to ciclosporin therapy following maternal renal transplantation were assessed (15 single pregnancies, 24 multiple pregnancies) and compared with 38 matched unexposed children. Intelligence, visuomotor abilities, and psychologic adjustment were measured using the Wechsler Preschool and Primary Scale of Intelligence-Revised (WPPSI-R), the Beery Developmental Test of Visual-Motor Integration (VMI-4) and the Wide Range Assessment of Visual Motor Abilities (WRAVMA), and the Child Behavior Checklist (CBCL), respectively. Statistical analysis, including regression, was performed to determine the significant predictors for the main outcome, full-scale IQ (FIQ). Results: There were no significant differences in FIQ, verbal IQ (VIQ), performance IQ (PIQ) or behavioral outcomes between exposed and unexposed children or between single and multiple delivery groups. Thirty-three percent of exposed children were premature versus 0.5% in unexposed controls (p < 0.01). Prematurity was associated with lowbirthweight, high rates of perinatal complications, and instrumental deliveries. Relative to fullterm children, premature, low birthweight children in the ciclosporin-exposed group had significantly lower FIQ and VIQ scores (101.04 vs 111.31 [p = 0.008] and 102.31 vs 113.08 [p = 0.021], respectively). Maternal IQ and socioeconomic status were positive and significant predictors for childrens IQ (p < 0.001 and p = 0.03, respectively). Therewere no statistically significant differences in exposed childrens IQwho were andwere not breastfed. Conclusion: In this cohort, there was no association between in utero exposure to ciclosporin and long-term neurocognitive and behavioral development in children after maternal renal transplantation. Maternal IQ and socioeconomic status are positive predictors for childrens intelligence. However, maternal renal transplantation and associated co-morbidity is associated with higher rates of premature delivery and consequent poorer neurocognitive and behavioral outcomes. Proper management of maternal morbidity and improved obstetric care may improve the childs profile.
AB - Background: Immunosuppressant therapy is essential in the prevention of organ transplant rejection. Objective: To evaluate the long-term neurodevelopmental outcomes of children following in utero ciclosporin (cyclosporine) exposure after maternal renal transplantation. Methods: A cohort study with matched controls using a prospectively collected database was conducted to assess neurocognitive and behavioral outcomes using standardized measures. Thirty-nine children exposed in utero to ciclosporin therapy following maternal renal transplantation were assessed (15 single pregnancies, 24 multiple pregnancies) and compared with 38 matched unexposed children. Intelligence, visuomotor abilities, and psychologic adjustment were measured using the Wechsler Preschool and Primary Scale of Intelligence-Revised (WPPSI-R), the Beery Developmental Test of Visual-Motor Integration (VMI-4) and the Wide Range Assessment of Visual Motor Abilities (WRAVMA), and the Child Behavior Checklist (CBCL), respectively. Statistical analysis, including regression, was performed to determine the significant predictors for the main outcome, full-scale IQ (FIQ). Results: There were no significant differences in FIQ, verbal IQ (VIQ), performance IQ (PIQ) or behavioral outcomes between exposed and unexposed children or between single and multiple delivery groups. Thirty-three percent of exposed children were premature versus 0.5% in unexposed controls (p < 0.01). Prematurity was associated with lowbirthweight, high rates of perinatal complications, and instrumental deliveries. Relative to fullterm children, premature, low birthweight children in the ciclosporin-exposed group had significantly lower FIQ and VIQ scores (101.04 vs 111.31 [p = 0.008] and 102.31 vs 113.08 [p = 0.021], respectively). Maternal IQ and socioeconomic status were positive and significant predictors for childrens IQ (p < 0.001 and p = 0.03, respectively). Therewere no statistically significant differences in exposed childrens IQwho were andwere not breastfed. Conclusion: In this cohort, there was no association between in utero exposure to ciclosporin and long-term neurocognitive and behavioral development in children after maternal renal transplantation. Maternal IQ and socioeconomic status are positive predictors for childrens intelligence. However, maternal renal transplantation and associated co-morbidity is associated with higher rates of premature delivery and consequent poorer neurocognitive and behavioral outcomes. Proper management of maternal morbidity and improved obstetric care may improve the childs profile.
KW - Children
KW - Ciclosporin, adverse reactions
KW - Developmental-disabilities
KW - In-utero-exposure
KW - Neurologic-manifestations
KW - Renal-transplant
UR - http://www.scopus.com/inward/record.url?scp=77949442075&partnerID=8YFLogxK
U2 - 10.2165/11316280-000000000-00000
DO - 10.2165/11316280-000000000-00000
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 20095652
AN - SCOPUS:77949442075
SN - 1174-5878
VL - 12
SP - 113
EP - 122
JO - Paediatric Drugs
JF - Paediatric Drugs
IS - 2
ER -